Adage Capital Partners Gp, L.L.C. Rigel Pharmaceuticals Inc Transaction History

Adage Capital Partners Gp, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $804,000 - $3.83 Million	-1,200,000 Reduced 63.16%	700,000 $791,000
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $4.01 Million - $6.23 Million	1,805,000 Added 1900.0%	1,900,000 $5.68 Million
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $224,200 - $339,150	95,000 New	95,000 $252,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.